Annovis Bio, Inc.
ANVS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001477845
No open-market purchases or sales by Annovis Bio, Inc. insiders were filed in the last 90 days; 61 institutions reported holding it in 13F filings for Q2 2026, worth $20.2M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Annovis Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Annovis Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hoffman Michael B | Director | 3,364,883 | May 21, 2026 | 7 |
| Bruck Claudine | Director | 13,709 | Nov 12, 2025 | 1 |
| Maccecchini Maria-Luisa | President & CEO | 1,212,020 | Nov 12, 2025 | 1 |
| Walsh Andrew | Vice President, Finance | 500 | Jun 18, 2025 | 0 |
| McCarthy Reid | Director | 9,305 | Jun 11, 2025 | 0 |
| White Mark K. | Director | 61,167 | Jul 3, 2024 | 0 |
| Hagopian Henry III | Chief Financial Officer | 1,820 | Nov 22, 2023 | 0 |
| McGroarty Jeffrey Brian | Chief Financial Officer | – | Jan 5, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 21, 2026 (view filing) | May 20 | 1 day | Hoffman Michael BDirector | PPurchase | +76.3K | $1.87 | +$142.8K | +2.3%3.36M after | 3 lots |
| Apr 3, 2026 (view filing) | Apr 2 | 1 day | Hoffman Michael BDirector | PPurchase | +713.8K | $2.10 | +$1.50M | +27.7%3.29M after | |
| Dec 8, 2025 (view filing) | Dec 8 | Same day | Hoffman Michael BDirector | PPurchase | +45.0K | $4.31 | +$193.8K | +1.8%2.57M after | 2 lots |
| Nov 25, 2025 (view filing) | Nov 24 | 1 day | Hoffman Michael BDirector | PPurchase | +39.2K | $4.08 | +$159.9K | +1.6%2.53M after | Amended4 lots |
| Nov 21, 2025 (view filing) | Nov 21 | Same day | Hoffman Michael BDirector | PPurchase | +20.0K | $3.50 | +$69.9K | +0.8%2.49M after | 2 lots |
| Nov 18, 2025 (view filing) | Nov 14 | 4 days | Hoffman Michael BDirector | PPurchase | +15.0K | $2.11 | +$31.6K | +0.6%2.47M after | |
| Nov 12, 2025 (view filing) | Oct 28 | 15 daysLate | Maccecchini Maria-LuisaPresident & CEO | PPurchase | +97.6K | $2.05 | +$200.0K | +8.8%1.21M after | |
| Nov 12, 2025 (view filing) | Oct 28 | 15 daysLate | Hoffman Michael BDirector | PPurchase | +975.6K | $2.05 | +$2.00M | +65.9%2.46M after | |
| Oct 13, 2021 (view filing) | Oct 11 | 2 days | Bruck ClaudineDirector | PPurchase | +181 | $27.66 | +$5.01K | +3.1%6.07K after | |
| Oct 13, 2021 (view filing) | Oct 12 | 1 day | White Mark K.Director | PPurchase | +5.00K | $27.40 | +$137.0K | +9.8%56.2K after | |
| Oct 13, 2021 (view filing) | Oct 11 | 2 days | Maccecchini Maria-LuisaPRESIDENT AND CEO | PPurchase | +18.0K | $27.61 | +$497.0K | +1.9%976.8K after | |
| Aug 23, 2021 (view filing) | Aug 19 | 4 days | McCarthy ReidDirector | PPurchaseCommon Stock, $0.0001 par value | +500 | $37.61 | +$18.8K | +7.9%6.83K after |